ArticlePediatric research2026
Value of anti-N-methyl D-aspartate receptor in children with encephalitis: a prospective observational study.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnti-N-methyl D-aspartate receptor (anti-NMDAR) encephalitis is a treatable autoimmune disorder increasingly recognized in children. We aimed to evaluate cerebrospinal fluid (CSF) anti-NMDAR antibody levels in pediatric encephalitis, and to assess their diagnostic and prognostic utility in relation to clinical, laboratory, and neuroimaging features
methodsIn this prospective observational study, 85 children with encephalitis admitted to the pediatric intensive care unit were evaluated. Patients were categorized into Group I (n = 37) with anti-NMDAR encephalitis and Group II (n = 48) with non-anti-NMDAR encephalitis. Clinical manifestations, CSF findings, Electroencephalogram (EEG), and CSF anti-NMDAR antibody levels (measured by ELISA) were analyzed. Receiver operating characteristic (ROC) curves assessed diagnostic performance
resultsGroup I demonstrated significantly higher rates of psychiatric symptoms, seizures, abnormal movements, and speech disturbances than Group II. EEG abnormalities, particularly extreme delta brush, were more common in anti-NMDAR encephalitis. CSF anti-GluN1 antibody levels correlated positively with alanine aminotransferase(ALT), platelet count, and Glasgow Coma Scale score (GCS), and negatively with CSF neutrophils and protein. Antibody levels were significantly elevated in Group I, with ROC analysis showing high sensitivity and specificity for diagnosis
conclusionCSF anti-NMDAR antibody measurement is a robust diagnostic biomarker in pediatric encephalitis. Early detection may facilitate timely immunotherapy and improve outcomes. IMPACT: This study demonstrates that CSF anti-NMDAR antibody testing improves both the diagnosis and prognosis of pediatric encephalitis. Antibody positivity was associated with distinct clinical and neuroimaging features, supporting earlier recognition and initiation of immunotherapy. Incorporating antibody testing into pediatric practice may enhance patient outcomes and advance the management of autoimmune encephalitis in children.
Identifiers
42086945What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.